About AdvanDx

Improving Diagnosis and Treatment of Critical Infections

AdvanDx is a healthcare solutions company driven to ensure early, appropriate antibiotic therapy for patients with bloodstream infections. Through a combination of rapid diagnostics and better clinical information, we’ve set out to improve health outcomes for patients, while reducing overall healthcare costs and unnecessary antibiotic use.

AdvanDx is the market leader in molecular testing of positive blood cultures enabling clinical microbiology labs to report pathogen identification results 48 to 72 hours earlier than conventional testing methods. When used by physicians and pharmacists to ensure early, appropriate antibiotic therapy for patients with bloodstream infections (a.k.a. septicemia), AdvanDx’s PNA FISH® tests have been shown in clinical studies to reduce patient mortality, shorten length of stay (LOS) and lower hospital costs.1,2

About Our Technology

AdvanDx employs a unique, Whole Cell Analysis (WCA) approach to pathogen identification using our proprietary Peptide Nucleic Acid Fluorescence In Situ Hybridization (PNA FISH) technology platform. This technology enables fast and highly accurate single cell analysis for species, resistance and virulence marker identification of bacterial cells found in samples from patients with critical infections.

1) Forrest et al. J Antimicro Chemo 2006; 58(1):154-158.
2) Forrest et al. Antimicrob Agents Chemo 2008; 52(10):3558-3563.